Comparison 1. Triptans versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1.1 Improvement in vertigo (global score)	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.1.1 Up to 2 hours	2	262	Risk Ratio (M‐H, Random, 95% CI)	0.84 [0.66, 1.07]
1.1.2 > 12 hours	1	170	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.90, 1.12]
1.2 Improvement in headache	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.2.1 Up to 2 hours	2	248	Risk Ratio (M‐H, Random, 95% CI)	0.69 [0.49, 0.96]
1.2.2 > 12 hours	1	171	Risk Ratio (M‐H, Random, 95% CI)	1.16 [0.99, 1.37]
1.3 Improvement in other migrainous symptoms	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.3.1 Nausea and vomiting at up to 2 hours	1	239	Risk Ratio (M‐H, Random, 95% CI)	0.80 [0.62, 1.03]
1.3.2 Nausea and vomiting at > 12 to 72 hours	1	170	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.93, 1.11]
1.3.3 Photo‐ and phonophobia at up to 2 hours	1	240	Risk Ratio (M‐H, Random, 95% CI)	1.05 [0.75, 1.47]
1.3.4 Photo‐ and phonophobia at > 12 to 72 hours	1	171	Risk Ratio (M‐H, Random, 95% CI)	1.20 [1.01, 1.42]
1.4 Other adverse effects	1		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
1.4.1 Gastrointestinal disturbance	1	114	Risk Ratio (M‐H, Random, 95% CI)	1.24 [0.60, 2.56]
1.4.2 Sleep disturbance	1	114	Risk Ratio (M‐H, Random, 95% CI)	2.41 [1.43, 4.07]
1.4.3 Cardiovascular side effects	1	114	Risk Ratio (M‐H, Random, 95% CI)	0.87 [0.22, 3.44]
1.4.4 Paraesthesia, flushing, warm or hot sensations	1	114	Risk Ratio (M‐H, Random, 95% CI)	0.73 [0.25, 2.14]
1.4.5 Headache	1	114	Risk Ratio (M‐H, Random, 95% CI)	0.75 [0.35, 1.60]